Cochrane · systematic review · CD012816
Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer
Sathianathen, NJ, Philippou, YA, Kuntz, GM, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
UrologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 57.1%Moderate 3 · 42.9%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) compared to ADT only for metastatic hormone‐sensitive prostate cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time to death due to any cause (absolute effect size estimates based on all‐cause mortality at 5 years) Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only | HR 0.77 [0.68, 0.87] | 3 studies · 2261 participants | Moderate Downgraded: risk of bias, imprecision |
Grade III to V adverse events Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only | RR 2.98 [2.19, 4.04] | 1 study · 375 participants | Low Downgraded: risk of bias, imprecision |
Prostate cancer‐specific death5 Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only | RR 0.79 [0.7, 0.89] | 3 studies · 2261 participants | Moderate Downgraded: risk of bias, imprecision |
Time to progression (absolute effect size estimates based on progression rate at 5 years) Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only | HR 0.63 [0.56, 0.71] | 3 studies · 2261 participants | Moderate Downgraded: risk of bias, imprecision |
Discontinuation due to adverse events Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only | RR 79.41 [4.92, 1282.78] | 1 study · 385 participants | Low Downgraded: risk of bias, imprecision |
All adverse events Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only | RR 1.11 [1.06, 1.17] | 1 study · 375 participants | Low Downgraded: risk of bias, imprecision |
Quality of life at 12 months ( Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only | no estimate extracted | 1 study · 790 participants | Low Downgraded: risk of bias, imprecision |